Gene mutation and RNA-Seq profile of 199 AML patient samples was interrogated, among which the mutation rates of TET2, DNMT3A, and FLT3 were 9%, 24%, and 29%, respectively (Figure 5B). This evidence concerns the gene DNMT3A and acute myeloid leukemia.